Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia Meeting Abstract
| Authors: | Schiller, G. J.; Tallman, M. S.; Goldberg, S. L.; Perl, A. E.; Marie, J. P.; Martinelli, G.; Larson, R. A.; Russell, N.; Trone, D.; Gammon, G.; Levis, M. J.; Cortes, J. E. |
| Abstract Title: | Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613203917 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.7100 |
| Notes: | Meeting Abstract: 7100 -- Source: Wos |
